Understanding CGRP Inhibitor Dosing: A Guide to Migraine Prevention Medications

CGRP (calcitonin gene-related peptide) inhibitors represent a significant advancement in migraine prevention therapy. These medications work by blocking CGRP pathways that play a key role in migraine development. Understanding proper dosing and administration is essential for both patients and healthcare providers to optimize treatment outcomes.

Ajovy (fremanezumab) is administered as a subcutaneous injection with two approved dosing regimens. The quarterly dosing option involves 675 mg (three 225 mg injections) given every three months, while the monthly option uses 225 mg given once monthly. Both regimens have demonstrated similar efficacy in clinical trials for migraine prevention.

Proper injection technique is important for all CGRP inhibitors. Ajovy should be administered subcutaneously in the thigh, abdomen, or upper arm, rotating injection sites with each dose. The medication should be brought to room temperature before injection and used within 24 hours of removal from refrigeration.

Patients considering CGRP inhibitors should discuss their complete medical history with their healthcare provider. These medications may not be suitable for everyone, and individual factors such as other medical conditions, current medications, and treatment goals should guide therapy selection. Regular follow-up appointments help ensure optimal treatment outcomes and allow for dosing adjustments if needed.